Table 1

Baseline characteristics.

NBARI/all
139
BARI/combo
46
BARI/mono
93
Age (years)Mean (SD)58.4 (12.8)56.2 (14.1)59.5 (12.0)
SexWomenN (%)98 (70.5)28 (60.9)70 (75.3)
MenN (%)41 (29.5)18 (39.1)23 (24.7)
Smoking statusNeverN (%)64 (46.0)24 (52.2)40 (43.0)
FormerN (%)43 (30.9)12 (26.1)31 (33.3)
CurrentN (%)32 (23.0)10 (21.7)22 (23.7)
Anti-CCP2 AbNegativeN (%)45 (32.4)17 (37.0)28 (30.1)
PositiveN (%)94 (67.6)29 (63.0)65 (69.9)
Duration (years)Mean (SD)9.7 (8.5)9.7 (7.5)9.6 (9.1)
Median (IQR)6.9 (3.5–13.8)7.5 (4.4–13.8)6.2 (3.0–13.8)
F/U (m)Mean (SD)68.9 (53.6)61.5 (48.9)72.5 (55.6)
Median (IQR)53.1 (23.0–109)47.6 (21.0–112)62.3 (23.1–105)
DAS-28 CRP(units)Mean (SD)4.0 (1.3)3.9 (1.3)4.0 (1.3)
DAS-28 ESR (units)Mean (SD)4.3 (1.3)4.2 (1.3)4.3 (1.3)
HAQ-DI (units)Mean (SD)1.1 (0.7)1.1 (0.6)1.2 (0.7)
VAS (global; mm)Mean (SD)52.4 (22.9)51.9 (21.9)52.6 (23.6)
VAS (physician; mm)Mean (SD)50.5 (19.9)47.9 (23.2)51.8 (18.0)
TJCMean (SD)6.8 (6.3)7.0 (7.2)6.8 (5.9)
SJCMean (SD)4.2 (5.0)4.1 (6.5)4.2 (4.2)
VAS painMean (SD)53.4 (21.5)50.4 (22.7)54.9 (20.9)
FACITMean (SD)30.1 (12.7)27.6 (14.1)31.4 (11.9)
RAIDMean (SD)5.1 (2.1)5.3 (2.2)5.0 (2.1)
HAQMean (SD)1.1 (0.7)1.1 (0.6)1.2 (0.7)
MTX dose at last useMedian (IQR)15.0 (15.0–20.0)15.0 (15.0–20.0)15.0 (15.0–20.0)
History of bDMARD useb-tsDMARD-naiveN (%)55 (39.6)16 (34.8)39 (41.9)
b_tsDMARD-IRN (%)84 (60.4)30 (65.2)54 (58.1)
Diabetes mellitusN (%)16 (11.9)3 (6.5)13 (14.6)
HypertensionN (%)55 (40.7)15 (32.6)40 (44.9)
  • Demographics, Disease Activity Score-28 (DAS 28 ESR/CRP), antibody status, follow-up time, disease duration, Health Assessment Questionnaire (HAQ), Functional Assessment of Chronic Illness Therapy (FACIT), Rheumatoid Arthritis Impact of Disease (RAID), visual analogue scales (VAS) for pain, global and physician, morning stiffness, 68 tender joint count (TJC) and 66 swollen joint count (SCJ) as well as comorbidities are shown for all patients as well as for the monotherapy and combination therapy arm: statistically no significant difference between the groups. The proportion of men and diabetic patients with RA, which are numerically more frequent in the BARI monotherapy arm without statistical significant differences.

  • BARI, baricitinib; bDMARDs, biologic disease modifying anti-rheumatic drugs ; RA, rheumatoid arthritis.